Research Papers:
miR-454 functions as an oncogene by inhibiting CHD5 in hepatocellular carcinoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1641 views | HTML 2289 views | ?
Abstract
Lei Yu1,*, Xuejun Gong2,*, Lei Sun3, Hong Yao1, Baoling Lu1, Liying Zhu1
1Department of Infectious Disease, The Fourth Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, China
2Department of Biliary and Pancreatic Surgery, Xiangya Hospital of Central South University, Changsha, 410008, Hunan, China
3Department of Ophthalmology, The Fourth Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, China
*These authors contributed equally to this work
Correspondence to:
Li-Ying Zhu, e-mail: [email protected]
Lei Yu, e-mail: [email protected]
Keywords: hepatocellular carcinoma, microRNA, miR-454, CHD5
Received: May 11, 2015 Accepted: July 17, 2015 Published: July 30, 2015
ABSTRACT
Previous studies showed that miR-454 acted as an oncogene or tumor suppressor in cancer. However, its function in HCC remains unknown. In this study, we found that miR-454 expression was upregulated in HCC cell lines and tissues. Knockdown of miR-454 inhibited HCC cell proliferation and invasion and epithelial mesenchymal transition (EMT), whereas overexpression of miR-454 promoted HCC cell proliferation and invasion and EMT. Furthermore, we identified the CHD5 as a direct target of miR-454. CHD5 was downregulated in HCC tissues and cell lines and the expression level of CHD5 was inversely correlated with the expression of miR-454 in HCC tissues. In addition, knockdown of miR-454 inhibited the growth of HepG2-engrafted tumors in vivo. Taken together, these results indicated that miR-454 functioned as an oncogene in HCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4407